Literature DB >> 22971477

ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo.

X P Sun1, X Zhang, C He, H Qiao, X Jiang, H Jiang, X Sun.   

Abstract

OBJECTIVE: This study investigated the potential synergistic effects of two inducers of apoptosis: the small molecule ABT-737 and arsenic trioxide (ATO).
METHODS: Human gastric carcinoma cell lines SGC-7901 and MGC-803 were used to determine the effects of ABT-737 and ATO (alone or in combination) on cell proliferation and apoptosis in vitro. In vivo effects of these drugs were investigated in SGC-7901 solid tumours, grown in immunodeficient mice.
RESULTS: ABT-737 and ATO inhibited proliferation and induced apoptosis in SGC-7901 and MGC-803 cells in concentration- and time-dependent manners, and showed a synergistic effect. ABT-737 disturbed the binding of B cell lymphoma (Bcl)-2 homologous antagonist killer and Bcl-extra large; ATO downregulated myeloid cell leukaemia (Mcl)-1 protein and upregulated Mcl-1short, the short splicing variant. ABT-737 and ATO significantly suppressed SGC-7901 xenograft growth, synergistically inhibited tumour growth and induced apoptosis in vivo.
CONCLUSIONS: This study provides preclinical evidence that ABT-737 and ATO synergize to induce apoptosis of gastric carcinoma cells, suggesting that further investigation of these agents (as potential treatments for gastric cancer) is warranted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22971477     DOI: 10.1177/147323001204000404

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  9 in total

1.  Enhanced anticancer effect of ABT-737 in combination with naringenin on gastric cancer cells.

Authors:  Haiyang Zhang; Xia Zhong; Xiao Zhang; Deya Shang; Y I Zhou; Chunqing Zhang
Journal:  Exp Ther Med       Date:  2015-12-04       Impact factor: 2.447

Review 2.  Gastric cancer: a comprehensive review of current and future treatment strategies.

Authors:  Rachel E Sexton; Mohammed Najeeb Al Hallak; Maria Diab; Asfar S Azmi
Journal:  Cancer Metastasis Rev       Date:  2020-09-07       Impact factor: 9.264

3.  Construction of a metabolomics profile of arsenic trioxide effect in gastric carcinoma cell line SGC7901.

Authors:  Ziqing Chen; Hainan Zhang; Lina Yang; Hewei Jiang; Shujuan Guo; Yang Li; Shengce Tao
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-04-03       Impact factor: 3.848

4.  Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.

Authors:  S M Woo; K-J Min; B R Seo; J-O Nam; K S Choi; Y H Yoo; T K Kwon
Journal:  Cell Death Dis       Date:  2014-11-06       Impact factor: 8.469

5.  A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenic trioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical.

Authors:  Ze Yang He; Hai Ying Li; Jiao Yan; Si Jin Li; Dao Cheng Li; Zhong Zhe Liang
Journal:  Trials       Date:  2022-07-08       Impact factor: 2.728

6.  Dimethyl celecoxib sensitizes gastric cancer cells to ABT-737 via AIF nuclear translocation.

Authors:  Bo Zhang; Youyou Yan; Yangling Li; Dan Zhang; Jianmei Zeng; Linling Wang; Mimi Wang; Nengming Lin
Journal:  J Cell Mol Med       Date:  2016-07-04       Impact factor: 5.310

7.  Arsenic trioxide induces the apoptosis and decreases NF-κB expression in lymphoma cell lines.

Authors:  Lu Zhong; Fei Xu; Fangyuan Chen
Journal:  Oncol Lett       Date:  2018-09-07       Impact factor: 2.967

8.  The Application of Arsenic Trioxide in Ameliorating ABT-737 Target Therapy on Uterine Cervical Cancer Cells through Unique Pathways in Cell Death.

Authors:  I-Lun Hsin; Ying-Hsiang Chou; Wei-Li Hung; Jiunn-Liang Ko; Po-Hui Wang
Journal:  Cancers (Basel)       Date:  2019-12-31       Impact factor: 6.639

Review 9.  Trace Elements in Human Nutrition (II) - An Update.

Authors:  Aliasgharpour Mehri
Journal:  Int J Prev Med       Date:  2020-01-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.